{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:47:44Z","timestamp":1793760464046,"version":"4.6.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016566","name":"Universit\u00e9 Mohammed VI Polytechnique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013371","name":"Universit\u00e9 C\u00f4te d\u2019Azur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022668","name":"OCP Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118236","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T22:41:28Z","timestamp":1760654488000},"page":"118236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Phosphorus-containing drugs: Expanding horizons in antiviral therapeutics"],"prefix":"10.1016","volume":"302","author":[{"given":"Hamza","family":"Tachallait","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Christina","family":"Pires Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Benhida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118236_bib2a","article-title":"A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19","author":"Belhadi","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ejmech.2025.118236_bib2b","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cmi.2023.01.007","article-title":"A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform","volume":"29","author":"Fawzy","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2025.118236_bib3","series-title":"Global HIV\/AIDS statistics\u20142024 Fact Sheet","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118236_bib4","series-title":"Report on the Hundred and Twenty-Sixth Session","year":"2009"},{"key":"10.1016\/j.ejmech.2025.118236_bib5","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0274","article-title":"Viral hepatitis and liver cancer","volume":"372","author":"Ringehan","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.118236_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2025.118236_bib8","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1021\/acs.jmedchem.0c00407","article-title":"Phosphine oxides from a medicinal chemist's perspective: physicochemical and in vitro parameters relevant for drug discovery","volume":"63","author":"Finkbeiner","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib9a","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cmdc.201800693","article-title":"The role of the phosphorus atom in drug design","volume":"14","author":"Rodriguez","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118236_bib9b","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1080\/17568919.2024.2423602","article-title":"The key phosphorus moieties in drug design: antimicrobials and beyond","volume":"16","author":"Vor\u00e1\u010dov\u00e1","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib10a","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100063","article-title":"Development and clinical application of phosphorus-containing drugs","volume":"8","author":"Yu","year":"2020","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118236_bib10b","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117512","article-title":"Harvesting phosphorus-containing moieties for their antibacterial effects","volume":"96","author":"Vor\u00e1\u010dov\u00e1","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.24875\/AIDSRev.20000135","article-title":"Global mapping of interventions to improve the quality of life of people living with HIV\/AIDS: implications for priority settings","volume":"23","author":"Tran","year":"2021","journal-title":"AIDS Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx252","article-title":"Aiming at the global elimination of viral hepatitis: challenges along the care continuum","volume":"5","author":"Heffernan","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118236_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.7326\/0003-4819-141-9-200411020-00006","article-title":"The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients","volume":"141","author":"Leung","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","article-title":"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study","volume":"18","author":"Beigel","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118236_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118236_bib17","series-title":"Coronavirus Disease (COVID-2019) Situation Reports","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118236_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2018.01.002","article-title":"The role of adjuvant immunomodulatory agents for treatment of severe influenza","volume":"150","author":"Hui","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41256-017-0055-6","article-title":"Use of a community-led prevention strategy to enhance behavioral changes towards Ebola virus disease prevention: a qualitative case study in Western C\u00f4te d'ivoire","volume":"2","author":"Gautier","year":"2017","journal-title":"Glob. Health Res. Policy"},{"key":"10.1016\/j.ejmech.2025.118236_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pt.2017.12.004","article-title":"How do virus\u2013mosquito interactions lead to viral emergence?","volume":"34","author":"R\u00fcckert","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2025.118236_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010457","article-title":"Socioeconomic disparities associated with symptomatic Zika virus infections in pregnancy and congenital microcephaly: a spatiotemporal analysis from Goi\u00e2nia, Brazil (2016\u20132020)","volume":"16","author":"Rosado","year":"2022","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.118236_bib22a","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1021\/bi0121858","article-title":"Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate","volume":"41","author":"Ray","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118236_bib22b","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/jm049029u","article-title":"Design, synthesis, and antiviral activity of adenosine 5\u2032-phosphonate analogues as chain terminators against hepatitis C virus","volume":"48","author":"Koh","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118236_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.18388\/abp.1996_4573","article-title":"Structure\u2013activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases","volume":"43","author":"Johansson","year":"1996","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2025.118236_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP2012","article-title":"Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy","volume":"22","author":"Pertusati","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618775243","article-title":"Phosphoramidates and phosphonamidates (ProTides) with antiviral activity","volume":"26","author":"Slusarczyk","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118236_bib30","article-title":"Avis relatif aux recommandations th\u00e9rapeutiques dans la prise en charge du COVID-19 (compl\u00e9mentaire \u00e0 l\u2019avis du 5 mars 2020)","year":"2020","journal-title":"Population (Paris)"},{"key":"10.1016\/j.ejmech.2025.118236_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118236_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib34","doi-asserted-by":"crossref","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children","volume":"10","author":"Chera","year":"2022","journal-title":"Discoveries"},{"key":"10.1016\/j.ejmech.2025.118236_bib35","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib36","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bmcl.2014.12.069","article-title":"Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro","volume":"25","author":"Tyndall","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118236_bib38a","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/med.21281","article-title":"A cutting-edge view on the current state of antiviral drug development","volume":"33","author":"De Clercq","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib38b","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1039\/C5CC00448A","article-title":"Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction","volume":"51","author":"Pertusati","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118236_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/9783527845088.ch07","article-title":"The discovery and development of sofosbuvir as the backbone of HCV curative therapies","author":"Sofia","year":"2025","journal-title":"Trends Antiviral Drug Dev"},{"key":"10.1016\/j.ejmech.2025.118236_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib41","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib42","article-title":"Remdesivir for the treatment of COVID-19","volume":"1","author":"Grundeis","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib43","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s40265-023-01926-0","article-title":"Remdesivir: a review in COVID-19","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78039-5","article-title":"Design of an innovative aptasensor for the detection of chemotherapeutic drug fludarabine phosphate","volume":"14","author":"Alanazi","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118236_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118236_bib46","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1128\/AAC.46.11.3613-3616.2002","article-title":"Stampidine is a potent inhibitor of zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations","volume":"46","author":"Uckun","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib47","first-page":"121","article-title":"Stampidine as a novel nucleoside reverse transcriptase inhibitor with potent anti-HIV activity","volume":"56","author":"Uckun","year":"2006","journal-title":"Drug Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib48","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1021\/acs.jmedchem.6b00523","article-title":"Nucleoside phosphate and phosphonate prodrug clinical candidates: miniperspective","volume":"59","author":"Thornton","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib49","first-page":"357","article-title":"Toxicity and pharmacokinetics of stampidine in mice and rats","volume":"53","author":"Uckun","year":"2003","journal-title":"Drug Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4172\/2155-6113.1000138","article-title":"Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate","volume":"3","author":"Cahn","year":"2012","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/13543784.2012.664635","article-title":"Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV\/AIDS","volume":"21","author":"Uckun","year":"2012","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib52","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1128\/AAC.00032-11","article-title":"Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methylguanosine","volume":"55","author":"Lam","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib53","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1128\/JVI.05639-11","article-title":"Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA","volume":"85","author":"Lam","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118236_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae331","article-title":"2\u2032-Fluorinated nucleoside chemistry for new drug discovery: achievements and prospects","volume":"11","author":"Meng","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/AAC.01101-10","article-title":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects","volume":"55","author":"Zhou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.2015.982274","article-title":"Discontinued drugs in 2012\u20132013: hepatitis C virus infection","volume":"24","author":"Gentile","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib57","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jmv.24736","article-title":"Quantitative structure\u2013activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human coronaviruses","volume":"89","author":"Elfiky","year":"2017","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2025.118236_bib58a","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1418516","article-title":"Recent advances in the study of Zika virus structure, drug targets, and inhibitors","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118236_bib58ab","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/1062936X.2018.1454981","article-title":"Molecular docking revealed the binding of nucleotide\/side inhibitors to Zika viral polymerase solved structures","volume":"29","author":"Elfiky","year":"2018","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib59a","article-title":"nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Anti-Hcv","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118236_bib59b","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118236_bib60","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/AAC.01335-10","article-title":"INX-08189, a phosphoramidate prodrug of 6-O-methyl-2\u2032-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties","volume":"55","author":"Vernachio","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib61","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1016\/j.bmcl.2010.06.094","article-title":"Synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus","volume":"20","author":"McGuigan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118236_bib62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.27488","article-title":"Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C","volume":"62","author":"Ahmad","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118236_bib63a","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.10.006","article-title":"The acyclic nucleoside phosphonates from inception to clinical use: historical perspective","volume":"75","author":"De Clercq","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib63b","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.antiviral.2006.05.020","article-title":"Perspectives on the development of acyclic nucleotide analogs as antiviral drugs","volume":"71","author":"Lee","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib64","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/j.bmc.2011.04.016","article-title":"New prodrugs of adefovir and cidofovir","volume":"19","author":"Tich\u00fd","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118236_bib65","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118236_bib66","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1135\/cccc19892190","article-title":"Synthesis of N-(2-phosphonylmethoxyethyl) derivatives of heterocyclic bases","volume":"54","author":"a Hol\u00fd","year":"1989","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118236_bib67a","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1135\/cccc19892470","article-title":"Synthesis of (3-hydroxy-2-phosphonylmethoxypropyl) derivatives of heterocyclic bases","volume":"54","author":"Hol\u00fd","year":"1989","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118236_bib67b","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1135\/cccc19930649","article-title":"Syntheses of enantiomeric N-(3-hydroxy-2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases","volume":"58","author":"Hol\u00fd","year":"1993","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118236_bib68","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118236_bib69","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0026-895X(25)09608-7","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118236_bib70a","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpesvirus agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118236_bib70b","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/0006-2952(94)90600-9","article-title":"Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylemthoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases \u03b2 and \u03b3","volume":"48","author":"Cherrington","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118236_bib70c","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/0006-2952(96)00100-1","article-title":"Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase","volume":"51","author":"Xiong","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118236_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/095632029600700301","article-title":"A new agent with potent anti-herpesvirus activity","volume":"7","author":"Hitchcock","year":"1996","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib72a","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib72b","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl) 9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib73a","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1081\/NCN-100002496","article-title":"Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood","volume":"20","author":"Eisenberg","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejmech.2025.118236_bib73b","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the HIV reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib74a","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/AAC.00968-06","article-title":"Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131","volume":"51","author":"Birkus","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib74b","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jproteome.5c00208","article-title":"Quantifying hydrolytic enzymes in the vitreous humor of humans and nonhuman species using targeted proteomics","volume":"24","author":"Ruttenberg","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ejmech.2025.118236_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/095632020801900205","article-title":"Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile: retroviruses and hepadnaviruses","volume":"19","author":"De Clercq","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib76","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","article-title":"Adefovir dipivoxil","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib77a","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118236_bib77b","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib78","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118236_bib79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/B978-0-7020-6896-6.00037-5","article-title":"Infections in the immunocompromised host","author":"Freeman","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2025.118236_bib80a","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/COH.0000000000000469","article-title":"Fostemsavir: a new CD4 attachment inhibitor","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2025.118236_bib80b","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118236_bib81","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib82","series-title":"FDA Approves New HIV Treatment for Patients with Limited Treatment Options","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118236_bib83","first-page":"17","article-title":"Newly approved HIV medications","volume":"45","author":"Grantner","year":"2020","journal-title":"US Pharm"},{"key":"10.1016\/j.ejmech.2025.118236_bib84a","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/135965350601100501","article-title":"Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance","volume":"11","author":"Canestri","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib84b","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/135965350701200310","article-title":"Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1","volume":"12","author":"Mathiesen","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib84c","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/v17050720","article-title":"Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short-and Long-Term Follow-Up","volume":"17","author":"Nigro","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118236_bib85a","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"Foscarnet","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib85b","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib85c","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Antiviral therapy of HSV-1 and -2","author":"Kimberlin","year":"2007"},{"key":"10.1016\/j.ejmech.2025.118236_bib86","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral therapies for herpesviruses: current agents and new directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib87","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/135965350701200608","article-title":"Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet","volume":"12","author":"Bonnafous","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib88a","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200464180-00014","article-title":"Fosamprenavir","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118236_bib88b","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir","volume":"45","author":"Wire","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118236_bib89a","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/AAC.00560-06","article-title":"Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers","volume":"51","author":"Ruane","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib89b","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/QAD.0b013e3280118d6a","article-title":"Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results","volume":"21","author":"Raquin","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2025.118236_bib90","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118236_bib91","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/AAC.01479-08","article-title":"Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects","volume":"53","author":"Zhou","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3851\/IMP2689","article-title":"Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)","volume":"19","author":"Margolis","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib93","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.05597-11","article-title":"Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects","volume":"56","author":"Zala","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118236_bib94","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bmcl.2011.12.038","article-title":"Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3\/4A protease with potent clinical activity","volume":"22","author":"Sheng","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118236_bib95","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP3132","article-title":"Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256","volume":"22","author":"Yang","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118236_bib96","series-title":"61st Annual Meeting of the American Association for the Study of Liver Diseases","article-title":"Safety, pharmacokinetics, and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256. Hepatology 52","author":"Goldwater","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118236_bib97","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(10)61199-3","article-title":"three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256","volume":"52","author":"Lawitz","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118236_bib98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118236_bib99","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(12)60026-9","article-title":"High SVR12 with 16 weeks of tegobuvir and GS-9256 with peginterferon-alfa 2a and ribavirin in treatment-naive genotype 1 HCV patients","volume":"56","author":"Nelson","year":"2012","journal-title":"J. Hepatol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:36:07Z","timestamp":1764624967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":120,"alternative-id":["S0223523425010013"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118236","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphorus-containing drugs: Expanding horizons in antiviral therapeutics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118236"}}